TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody ...

Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate targeting HER2 but paradoxically efficient even in breast cancers expressing HER2 at very low levels. Here authors show that invasive ...

Big pharma companies like Pfizer are making significant investments in antibody-drug conjugates, a promising class of therapies. This article explores the growing interest and recent developments ...

Discover real-time ImmunoPrecise Antibodies Ltd. Common Stock (IPA) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.